Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.41 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.41 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.41 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.41 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.41 |
| ▸ | GNAI3 | P08754 | 3/20 | 0.39 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.39 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.39 |
| ▸ | NPY1R | P25929 | 2/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
| ▸ | YES1 | P07947 | 1/20 | 0.35 |
| ▸ | LYN | P07948 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | FGR | P09769 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7220748 | 0.98 | ALOX15 (0.48) | ALOX15PRMT3CARM1PRMT6PRMT1 | |
| SCHEMBL12714667 | 0.88 | KDM1A (0.43) | ALOX15HRH3KDM1A | |
| SCHEMBL22856515 | 0.83 | ALOX15 (0.46) | ALOX15PRMT3CARM1PRMT6PRMT1 | |
| SCHEMBL17284210 | 0.82 | L3MBTL3 (0.37) | NPY1RNOS3NOS1NOS2ABL1 | |
| SCHEMBL10223659 | 0.80 | DRD2 (0.44) | GNAI3GNAO1GNAI1NPY1RNOS3 | |
| SCHEMBL1307796 | 0.79 | ALOX15 (0.46) | ALOX15PRMT3CARM1PRMT6PRMT1 | |
| SCHEMBL22823535 | 0.78 | NPY1R (0.38) | CARM1PRMT6PRMT1PRMT8NPY1R | |
| SCHEMBL15956482 | 0.78 | NPY1R (0.43) | NPY1RL3MBTL3CYP3A4CYP2C9KCNH2 | |
| SCHEMBL1786190 | 0.78 | NPY1R (0.38) | CARM1PRMT6PRMT1PRMT8NPY1R | |
| SCHEMBL17443360 | 0.78 | NPY1R (0.38) | CARM1PRMT6PRMT1PRMT8NPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11945798-B2 | Substituted aminopyridine compounds as EGFR inhibitors | YUHAN CORPORATION (KR) | 2024-04-02 | — | — | US | disclosed |
| US-20230086795-A1 | SUBSTITUTED AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS | YUHAN CORPORATION (KR) | 2023-03-23 | — | — | US | disclosed |
| WO-2023027515-A1 | SUBSTITUTED AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS | YUHAN CORPORATION (KR) | 2023-03-02 | — | — | WO | disclosed |
| US-20220259226-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2022-08-18 | — | — | US | disclosed |
| US-11208381-B2 | Indole derivatives and their use as protein kinase inhibitors | RESPIVERT LIMITED (GB) | 2021-12-28 | — | — | US | disclosed |
| US-11208381-B2 | Indole derivatives and their use as protein kinase inhibitors | RESPIVERT LIMITED (GB) | 2021-12-28 | — | — | US | disclosed |
| US-20210292339-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2021-09-23 | — | — | US | disclosed |
| US-20210114982-A1 | INDOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2021-04-22 | — | — | US | disclosed |
| US-20210114982-A1 | INDOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2021-04-22 | — | — | US | disclosed |
| US-20200255451-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2020-08-13 | — | — | US | disclosed |
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | NOVARTIS AG (CH) | 2010-05-20 | — | — | US | disclosed |
| CN-101679382-A | 3-imidazolyl-indoles for the treatment of proliferative diseases | NOVARTIS AG | 2010-03-24 | — | — | CN | disclosed |
| EP-2142535-A2 | 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis Ag (CH) | 2010-01-13 | — | — | EP | disclosed |
| US-20090163465-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-20090163465-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-20090149438-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-11 | — | — | US | disclosed |
| US-20090149438-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-11 | — | — | US | disclosed |
| US-7521457-B2 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-21 | — | — | US | disclosed |
| US-7521457-B2 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-21 | — | — | US | disclosed |
| WO-2008119741-A2 | 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11945798-B2 | Substituted aminopyridine compounds as EGFR inhibitors | EGFR, ERBB2, ERBB4 | ALOX15 4868/4885PRMT3 298/4885CARM1 1706/4885 |
| US-20210292339-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | ALOX15 2524/4885PRMT3 523/4885CARM1 1297/4885 |
| US-11208381-B2 | Indole derivatives and their use as protein kinase inhibitors | GRK3, IDO1, CIT | ALOX15 3252/4885PRMT3 232/4885CARM1 858/4885 |
| US-20090163465-A1 | Pyrimidines as PLK inhibitors | PLK2, PLK3, TYMP | ALOX15 2650/4885PRMT3 622/4885CARM1 1501/4885 |
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | MDM4, TP53, MDM2 | ALOX15 3177/4885PRMT3 116/4885CARM1 913/4885 |
| US-20090149438-A1 | Pyrimidines as PLK inhibitors | PLK2, PLK3, TYMP | ALOX15 2650/4885PRMT3 622/4885CARM1 1501/4885 |
| US-20230086795-A1 | SUBSTITUTED AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS | EGFR, ERBB2, ERBB4 | ALOX15 4868/4885PRMT3 298/4885CARM1 1706/4885 |
| US-20200255451-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | ALOX15 2524/4885PRMT3 523/4885CARM1 1297/4885 |
| US-20210114982-A1 | INDOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | GRK3, IDO1, CIT | ALOX15 3252/4885PRMT3 232/4885CARM1 858/4885 |
| US-20220259226-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | ALOX15 2524/4885PRMT3 523/4885CARM1 1297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.